Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Company�s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company�s product candidate, obeticholic acid, or OCA, is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid. OCA selectively binds to and induces activity in the farnesoid X receptor, or FXR, which has broad liver-protective properties. The Company is developing OCA initially for primary biliary cirrhosis, or PBC, as a second line treatment for patients who have an inadequate response to or who are unable to tolerate standard of care therapy and therefore need additional treatment. It is conducting a Phase III clinical trial of OCA in PBC. Its other products are INT-767 and INT-777.